EICHORPublic-registry site landscape for NCT01464034, “A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma”, a Multiple Myeloma study sponsored by Criterium, Inc.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT01464034 (registry record) |
| Study title | A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma |
| Official title | A Multi-Center Phase I/II, Open-Label, Dose-Finding Pilot Study of the Combination of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma |
| Sponsor | Criterium, Inc. |
| Condition(s) | Multiple Myeloma |
| Phase | PHASE1 / PHASE2 |
| Listed sites | 9 |
| Site countries | United States |
Patient-friendly overview of this study: eichor.com/study/NCT01464034.
Eichor generates a preliminary site-risk snapshot for NCT01464034 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Multiple Myeloma trials
More from Criterium, Inc.
← Eichor home · All tracked trials · Multiple Myeloma studies · Weekly briefs
